Navigation Links
Neurologix Announces Second Quarter 2011 Financial Results
Date:8/11/2011

d June 30, 2011 and June 30, 2010.

For the six months ended June 30, 2011, Neurologix reported a net loss of approximately $5.0 million, as compared with a net loss of approximately $8.0 million for the six months ended June 30, 2010. Net loss for the six months ended June 30, 2011 includes other income of approximately $2.7 million recognized for the change in estimated fair value of the Company's derivative financial instruments relating to certain warrants issued in connection with the Notes, the Series C Stock and the Series D Stock, as well as interest expense related to the Notes of approximately $2.7 million. Net loss for the six months ended June 30, 2010 included charges of approximately $2.6 million recognized for the change in estimated fair value of the Company's derivative financial instruments relating to warrants issued in connection with the Series D Stock and the Series C Stock.

The Company reported a net loss applicable to common stock for the six months ended June 30, 2011 of approximately $6.7 million, or $0.24 per basic and diluted share, as compared with a net loss applicable to common stock for the six months ended June 30, 2010 of approximately $9.5 million, or $0.34 per basic and diluted share. Net loss applicable to common stock includes charges related to preferred stock dividends in connection with the Series D Stock and the Series C Stock of approximately $1.7 million, or $0.06 per basic and diluted share, for the six months ended June 30, 2011, and approximately $1.6 million, or $0.06 per basic and diluted share, for the six months ended June 30, 2010.

The Company had cash and cash equivalents of approximately $3.5 million as of June 30, 2011.

Clark A. Johnson, President and Chief Executive Officer of Neurologix, noted that these second quarter financial results were consistent with the Company's expectations. "Neurologix continues to advance the clinical development of NLX-P101, the Company's novel, investi
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
2. Bion Announces New U.S. Patent for Phosphorus Removal
3. ViaCyte Announces Executive Management Changes
4. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSELā„¢ Technology Being Developed to Treat Osteoporosis
5. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
6. Osteologix Announces Completion of Corporate Consolidation
7. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
8. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
9. Rigel Announces Second Quarter 2011 Financial Results
10. WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
11. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
(Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics software ... a new partner. STT-Systems has developed an impressive ... with offerings in the optical-motion capture, 3D scanning, and industrial ... unit), iSen, is opening eyes around the world. With no ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... Conference Call and Webcast Scheduled --BRISBANE, Calif., April 20 ... InterMune and Pharmasset, Inc. will host a live webcast of ... on Saturday, April 25, 2009, at 7:00 p.m. CEST (1:00 ... Gane, M.D., principal investigator in the INFORM-1 trial. Members ...
... (LSE: SHP,NASDAQ: SHPGY ), the global specialty biopharmaceutical company, will announce,first ... Results press release will be issued at: ... ... Live conference call for investors: , Angus Russell, ...
... 750 FAST is Presented at AACR 100th Annual MeetingBEDFORD, ... in fluorescence in vivo imaging from research ... FAST ("Fluorescent Activatible Sensor Technology") imaging agent ... drug response in vivo . Newly developed ...
Cached Biology Technology:InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25 2Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009 2VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo 2VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo 3VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo 4
(Date:12/17/2014)... 15, 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a ... introduces for the first time a fingerprint sensor in ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... in the Journal of Trauma and Acute Care ... spinal cord-injured patients is successful not only in weaning ... to independent respiration, where they could breathe on their ... The stimulation is provided by the Diaphragm Pacing ...
... As the Endangered Species Act (ESA) celebrated its 40th anniversary at ... Wildlife Service (USFWS), was mired in controversy. At issue was a ... the List of Endangered and Threatened Wildlife and add the Mexican ... a result, the USFWS sought an independent peer review of the ...
... shape might be just as important in a biology lab ... role in the effectiveness of cells grown to repair or ... structures that enable cells to "shape up," researchers at the ... with a way to measure, and more importantly, classify, the ...
Cached Biology News:Diaphragm pacing in spinal cord injury successful in weaning patients from ventilators 2Diaphragm pacing in spinal cord injury successful in weaning patients from ventilators 3Panel issues report on gray wolf science 2Shape-sifting: NIST categorizes bio scaffolds by characteristic cell shapes 2
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... produces output at 470 nm; includes interface cable ... or installed into rack or desktop boxes ... is an LED that produces either pulsed or ... region -- for fluorescence measurements. The source is ...
... miRCURY Array LNA microarray slides ... Array microarray slides incorporate Exiqons unique Locked ... sensitivity and excellent mismatch discrimination for short ... on less than 1 g total RNA ...
... amber to slightly cloudy liquid. Yellow, ... per set, each containing 10 ml ... the following proportions by weight: 85% ... monooleate emulsifier), and 0.1% Mycobacterium ...
Biology Products: